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What is it? Human immunodeficiency
virus, a retrovirus that causes acquired
immune deficiency syndrome
(AIDS) in humans. There are two
main types, HIV-1 and HIV-2, as well
as a simian virus (SIV) that causes
AIDS in macaque monkeys.
Also known as… the AIDS virus. 
Why all the fuss about HIV? There are
currently more than 35 million people
infected with HIV. In 1998, 2.3 million
people died of AIDS worldwide, twice
as many as the year before.
Where did it come from? HIV-1
probably came from chimpanzees in
Africa and HIV-2 from West African
Sooty mangabey monkeys. 
So does HIV really cause AIDS? Peter
Duesberg, an eminent virologist, has
made headlines by claiming it doesn’t.
He pushes the view that AIDS is
caused by drug abuse and by AZT, an
antiretroviral drug that has been used
for years to treat HIV-infected people.
Is there any substance to Duesberg’s
argument? No.
Seriously, though, what is the evidence
that HIV causes AIDS? HIV can be
detected in virtually everybody with
AIDS and HIV fulfils Koch’s
postulates — microbiology’s gold
standard — as the cause of AIDS.
What HIV research is in vogue at the
moment? Triple-drug ‘combination’
therapy (see below) and HIV
coreceptors. It was known 10 years
ago that HIV needs CD4, a
cell-surface receptor, to gain entry
into cells, but it was also clear that
CD4 is not enough: the virus needs a
second cell-surface molecule before it
can infect and kill a cell. Two years
ago the chemokine receptors CCR5
and CXCR4 were identified as the
coreceptors used by HIV isolates that
infect macrophages and T-cell lines,
respectively. Now eight more related
molecules have been added to the list.
So is there much published about HIV?
There have been more than 70,000
papers on HIV in the past 10 years. 
Is there a cure for AIDS? Not yet. Until
two years ago there was really no way
of controlling AIDS except to treat
the opportunistic infections that occur
mainly as a result of the progressive
loss of ‘memory’ CD4-bearing
T lymphocytes. A dramatic advance
has been the development of highly
active anti-retroviral treatment
(HAART), a combination of drugs —
such as inhibitors of proteases and
reverse transcriptase — that inhibit
different stages of the viral life cycle.
HAART greatly decreases plasma
HIV-1 RNA concentrations and
increases numbers of CD4+ T cells,
even in patients with advanced
disease. It can stop AIDS progression,
diminish opportunistic infections and
reduce death rates. But many patients
cannot tolerate HAART long-term,
and about 90% of infected people live
in countries that cannot afford such
costly drug therapies.
Are some people genetically resistant to
HIV infection? Yes… at least, to some
strains. Some individuals who remain
uninfected despite exposure to HIV
are homozygous for a deletion in the
CCR5 coreceptor gene; but a small
number of such individuals have
become infected with HIV strains
that use CXCR4 as their coreceptor.
Is there cause for hope?
Glaxo Wellcome has announced that
it will provide AZT at substantially
reduced cost to HIV-positive pregnant
women in the developing world. This
should help reduce the estimated
550,000 infections from mother to
child each year. In a 1994 clinical trial,
an AZT regimen given to pregnant,
non-breastfeeding HIV-positive
women reduced the risk of perinatal
HIV transmission by almost 70%.
Can HAART eradicate HIV? With a
combination of at least three drugs, it
is unlikely that a virus will emerge
that is resistant to all three drugs
simultaneously — but it is still
possible. The drugs are only effective
against virus that is replicating, and
not against virus resting in latently
infected cells — some of which, such
as brain cells, are long-lived and
remain a potential source of virus for
many years. HIV survives an immune
onslaught from the moment of
transmission, so there is little
optimism for a strategy of stimulating
the immune system to finish the
virus off. Clearly, a vaccine is needed.
What is the difficulty in producing a
vaccine? HIV is notoriously variable
(each individual harbours a distinct
population of viruses), especially in
the envelope protein, the target for
neutralising antibodies. Also, it is not
known which arm of the immune
system — cytotoxic T lymphocytes or
neutralising antibodies — is most
effective at eliminating HIV. There is
no small-animal model for HIV
infection, to help in evaluating
vaccines. Several candidate vaccines
will soon be clinically tested but there
is little evidence so far of efficacy.
Don’t say… HIV doesn’t cause AIDS.
It really does. 
Do say… Use a condom! Preventing
HIV transmission remains the most
reliable method of controlling AIDS.
Where can I find out more?
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